Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma
Status:
Terminated
Trial end date:
2019-03-20
Target enrollment:
Participant gender:
Summary
This study will be conducted in 2 parts. The phase 1b part will be an international, phase
1b, open-label, dose-escalation assessment of radium-223 dichloride administered with
bortezomib and dexamethasone in subjects with relapsed multiple myeloma. The primary endpoint
is to determine the optimal dose of radium-223 dichloride in combination with
bortezomib/dexamethasone for the Phase 2 portion of the study.
The phase 2 part will be an international, phase 2, double-blind, randomized,
placebo-controlled assessment of radium-223 dichloride versus placebo administered with
bortezomib and dexamethasone, in subjects with relapsed multiple myeloma.
Up to 12 subjects in all dose cohorts combined will be treated in the phase 1b part of the
study. Up to approximately 100 subjects will be enrolled in the phase 2 part of the study.